<DOC>
	<DOCNO>NCT02533219</DOCNO>
	<brief_summary>The primary objective study evaluate utility [ 18F ] -DOPA PET provide improved presurgical plan distinguish focal diffuse form HI . The investigator perform descriptive analysis , rely visual analysis diagnose localize focal lesion . Our finding compare surgical histopathology determine sensitivity specificity technique . The investigator also track patient surgical outcome , specifically whether patient surgically `` cure '' still require medical management control residual hypoglycemia .</brief_summary>
	<brief_title>Study Use 18F-DOPA Hyperinsulinemic Hypoglycemia</brief_title>
	<detailed_description>Hyperinsulinemic hypoglycemia cause low glucose due excessive insulin secretion remain difficult treat requirement extensive amount glucose lack effective long-term medical therapy . Correct diagnosis , localization , limited excision focal lesion result complete cure patient . In contrast , medically unresponsive diffuse disease require near total pancreatectomy , greatly increase risk future diabetes mellitus . Fortunately , [ 18F ] -DOPA PET show useful noninvasive imaging method distinguish focal diffuse form hyperinsulinemic hypoglycemia . In study , investigator seek validate effectiveness use PET/MR PET/CT F-DOPA accurately reliably detect localize disease .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<criteria>All Patients clinically diagnose Hyperinsulinemia age Patients need PET scan Patients require sedation Patients require sedation Subjects present follow include study : Patients without Hyperinsulinemia Patients may pregnant Serious intercurrent medical illness hypoglycemia precludes scan either patient instability concern potential toxicity . Patient 's require emergency surgical intervention would inappropriately delay [ 18F ] DOPA PET imaging .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hyperinsulinemic hypoglycemia</keyword>
	<keyword>PET/CT</keyword>
	<keyword>PET/MRI</keyword>
	<keyword>[ 18F ] -DOPA</keyword>
	<keyword>PET/MR</keyword>
	<keyword>Congenital Hyperinsulinism</keyword>
</DOC>